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T
he American College of Endocrinol-
ogyheldaConsensusConferencein
Washington, DC, on 21–22 July
2008 on the topic of pre-diabetes, orga-
nizedaroundaseriesofinterrelatedques-
tions. This is the ﬁrst of a three-part
series summarizing presentations at the
conference.
What should be the criteria for
diagnosis of nondiabetes,
pre-diabetes, and diabetes?
Michael Stern (San Antonio, TX) opened
the conference by discussing approaches
toidentifyingpre-diabetes,notingthat,of
course, there is always pre-diabetes be-
fore diabetes and that, of course, diabetes
is associated with a number of complica-
tions such that pre-diabetes cannot be
considered a benign condition (as it is
clearly associated, for example, with in-
creased cardiovascular risk). Pre-diabetes
is, however, an asymptomatic condition
not associated with functional impair-
ment, Stern argued, suggesting that if a
state is associated with future morbidity
andmortality,oneshouldnotusethepar-
adigm of treating illness in devising ap-
proaches to manage the condition. Citing
the adage “prediction is very difﬁcult, es-
pecially about the future,” variously at-
tributed to Niels Bohr and Yogi Bera, he
pointed out that predictions applying to a
group differ somewhat from those apply-
ing to individuals. He reviewed a well-
recognized approach to assessing the
performance of continuous risk factors,
the receiver operating characteristic
(ROC) curve of sensitivity vs. false-
positive rate, with the area under the
curve(AUC)ameasureofthereliabilityof
the test, ranging from 0.5 for a test no
better than a ﬂip of a coin to 1.0 for a
completely reliable test (1). Relative risk
ratios that are considered important are
associated with a very modest AUCROC,
with an odds ratio of 1.5 only associated
with an AUCROC of 0.56 and relative risk
ratios of 9–10 required for AUCROC
0.8. It should be noted, however, that
the analysis to which Stern referred sim-
plynotedthecomplexityofrelativeriskin
establishing disease likelihood in an indi-
vidual of a population with modest a pri-
ori disease risk, such that the population-
attributableriskforathreefoldincreasein
relative risk may be quite substantial.
Sternemphasizedwhatheconsidered
to be the greater usefulness of continuous
rather than dichotomous risk scores.
With the latter, sensitivity, speciﬁcity,
and target population are ﬁxed, while
with the former all are ﬂexible if one
“tweaks the cut point,” allowing one to
optimize test behavior. He suggested that
a continuous risk score such as the Fra-
mingham equation predicting 10-year
likelihood of cardiovascular disease is
moreusefulthanadichotomousmeasure,
such as, in a sense, the concept of pre-
diabetes. Using data from a San Antonio
epidemiologicstudy,hisgroupcalculated
a diabetes risk score, showing it to be a
betterpredictiveapproachthaneitherim-
paired fasting glucose (IFG) (fasting glu-
cose100–125mg/dl)orimpairedglucose
tolerance (IGT) (glucose 2-h postload
75-g oral glucose 140–199 mg/dl). The
model includes as factors age, sex, His-
panic vs. non-Hispanic white ethnicity,
fasting glucose, systolic blood pressure,
HDLcholesterol,BMI,andfamilyhistory,
although Stern noted that ethnicity limits
thedegreetowhichthemodelcanbegen-
eralized (2). The model has somewhat
better ability to predict diabetes than ei-
ther fasting or postload blood glucose
alone. Furthermore, Stern noted, the use
of variables such as LDL cholesterol al-
lows considerably greater cardiovascular
diseasepredictionthanavailablewithIFG
andIGT,similartotheperformanceofthe
Framingham model (3).
To establish that risk factors are valid
for predictive models, a prospective co-
hort study must be performed with the
new risk factor along with conventional
risk factors measured at baseline, with
outcomes of interest measured at follow-
up, and with independent validation
datasetsshowingthesamecharacteristics.
“A considerable effort is required to im-
prove upon the models that we already
have,” Stern said. An important barrier to
adoption of predictive models is that
health professionals tend to consider that
they lack naturally occurring cut points,
he noted. In fact, however, cut points for
established risk factors such as glucose,
blood pressure, and lipids also tend to be
arbitrary, as are the various criteria used
for metabolic syndrome. He concluded
that the notion of pre-diabetes as a condi-
tionnecessitatingtreatmentrequirescare-
ful examination. It is an asymptomatic
state, the signiﬁcance of which lies in its
abilitytopredictadversehealthoutcomes
for individuals diagnosed. As there is no
evidence that early intervention (prior to
diagnosis of diabetes) is better than late
intervention (after diabetes is present), he
suggestedthat“itisaveryprofoundques-
tion” as to whether the concept of pre-
diabetesshouldbeappliedtoindividuals.
Rather, he suggested, it needs to be dem-
onstrated, both in terms of cost versus
beneﬁt and in terms of outcome, at what
pointglycemicinterventionshouldbegin;
strong clinical trial data for glucose inter-
ventions, just as we now have for lipid
and blood pressure interventions, must
be developed.
Jacqueline Dekker (Amsterdam, the
Netherlands) discussed the Hoorn Study,
emphasizing the need for evidence-based
prevention of diabetes and vascular com-
plications.Shediscussedthecomplexhis-
tory of criteria for diabetes and pre-
diabetes. The World Health Organization
(WHO) and the American Diabetes Asso-
ciation (ADA) deﬁnitions of diabetes ac-
cept fasting plasma glucose 126 mg/dl
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load levels 200 mg/dl (11.1 mmol/l).
In 2003, the ADA suggested that the
lowerlimitofIFGbereducedfrom110to
100 mg/dl, putting it in conﬂict with the
WHO guidelines. Genuth and Kahn have
recently argued that neither IGT nor IGT
is useful (4). Recently, there have been
proposals that A1C should be used in the
diagnosis of diabetes (5). There are, then,
a number of approaches to assessing dia-
betesrisk:thosebasedondirectmeasures
(IFG and IGT) and those based on mark-
ers like A1C and the presence of meta-
bolicsyndrome.Dekkerproposedthatwe
endeavor to understand the performance
of the differing deﬁnitions and the preva-
lence of the (pre-) disease states so de-
ﬁned, their agreement, and their
associations with cardiovascular disease
(CVD) and with diabetes from the dual
perspectives of clinical care and public
health interests.
The Hoorn study began in 1989–
1990, involving 2,484 men and women
ages 50–75 years, with follow-up evalua-
tions performed in 1996, 2000, 2005,
and2007includingoralglucosetolerance
testing (GTT), A1C, lipids, blood pres-
sure, and anthropometric measures. Us-
ing the WHO criterion with a cut point of
110 mg/dl, 12% had IFG, while 35% had
IFG by the ADA criterion of 100 mg/dl; 5
and 4% had newly diagnosed and previ-
ously known diabetes, respectively. Oth-
ershavereportedasimilarincreaseinIFG
with the lower ADA criterion (6). Conse-
quently, individuals with IGT satisfying
the ADA criterion have considerably
lowerriskofdiabetesthanthosesatisfying
theWHOcriterion(7).IntheHoorndata-
set, individuals with either IFG (based on
fastingglucose110mg/dl)orIGTalone
had33–34%6-yearcumulativeincidence
of diabetes, while 65% of those having
both elevated fasting and 2-h glucose de-
veloped diabetes during the same period
(8). Hoorn study data comparing glucose
tolerancein1998and2005similarlysug-
gested that the 110 mg/dl cut point more
strongly predicts CVD mortality than the
100 mg/dl cut point (9). Dekker showed
data from the Diabetes Epidemiology:
Collaborative Analysis of Diagnostic Cri-
teriainEurope(DECODE)studyfavoring
theuseof2-hglucosewithoutathreshold
formortality,asthe2-hglucoseincreased
from3to11.1mmol/l/l,whilethereis
adeﬁnitedifferenceinoutcomeforfasting
glucose between 7 and 7 mmol/l/l
(10). Similar evidence of greater associa-
tion with mortality of 2-h than of fasting
glucose was found in analysis of the Ath-
erosclerosis Risk in Communities study
(11).
Addressing the use of A1C in pre-
diabetes, Dekker noted that 10% of the
nondiabetic population in the Hoorn
studyhadA1C6%,withthepercentage
only increasing to 16% of the IFG/IGT
population. There was a weak correlation
of A1C with fasting glucose and an even
weaker correlation of A1C with 2-h glu-
cose among nondiabetic individuals.
Dekker reviewed the concept that there is
heterogeneity in the degree to which dif-
ferent people glycate hemoglobin for a
given blood glucose concentration. In the
Islington Diabetes Survey, only 19–41%
of the variance in glycated hemoglobin
was explained by the 2-h glucose (12).
Althoughaproposaliscurrentlybeingad-
vanced that A1C should be expressed as
an estimated average glucose (13), only a
small number of nondiabetic people have
beenstudiedinthisfashion.Thereappear
to be genetic determinants of A1C (14),
with differing degrees of hemoglobin gly-
cation potentially related to differences in
erythrocyte survival, different intracellu-
lar oxygen tension, 2,3-diphosphoglycer-
ate levels, pH, or different degrees of
erythrocyte permeability to glucose.
(Moreinformationonthispointispresent
inarecentanalysisofthetopicofvariabil-
ity in the relationship between glucose
and A1C [15]). Dekker did, however, re-
view intriguing information from the
Hoorn study suggesting a relationship of
A1C with CVD risk, both in male and fe-
male subjects, with much but not all of
the increase in risk explained by other
CVD risk factors; she noted that similar
reports have been made from analysis of
other epidemiological studies and that
A1C is also associated with future risk of
microalbuminuria and retinopathy.
Dekkerconcludedbydiscussingmet-
abolic syndrome as a marker of pre-
diabetes, noting that its many deﬁnitions
give rise to high variability in reported
prevalence. Metabolic syndrome is asso-
ciated with increase in the risks of diabe-
tes (most but not all of which are due to
glucose as a factor) and CVD, with heter-
ogeneity between studies (16), presum-
ably due largely to the use of different
deﬁnitions. The rationale for the para-
digm that insulin resistance underlies
both diabetes and CVD has recently been
questioned. Hyperinsulinemic-euglyce-
mic clamp studies of 1,308 nondiabetic
individuals show remarkably little over-
lap between the upper quartiles of large
waist, insulin resistance, and hyperinsu-
linemia(17).Intheanalysis,insulinresis-
tance was much more strongly associated
with 2-h than with fasting glucose but
also showed associations with free fatty
acid and triglyceride levels, suggesting
that many of the physiologic assumptions
of metabolic syndrome need reevalua-
tion. Dekker concluded that proposed
deﬁnitions of pre-diabetes vary greatly
with respect to a number of factors as a
result of heterogeneity between individu-
als with hyperglycemia within the normal
range. As with any condition, the bulk of
people who will develop diabetes have
only modest increase in risk, such that
approaches appropriate for overall popu-
lations may be rather different from indi-
vidual treatment recommendations.
Pharmacologicinterventionwithglucose-
loweringagentsorotherdrugsdirectedat
CVD will only be appropriate with high-
risk patient programs individually fo-
cused on intensive lifestyle behavior
modiﬁcation, but this does not preclude
more general population–focused life-
style campaigns.
Barbara Viventi Howard (Washing-
ton, DC) discussed CVD-hyperglycemia
associations from the Strong Heart Study,
discussing impaired glucose and pre-
diabetes versus diabetes relationships to
CVD risk factors and the prediction of
CVD. A caveat is the degree of interindi-
vidual and interlaboratory variability in
glucose values, which may change mark-
edly on retesting. She cited a study per-
formed by William Knowler showing
that, for IFG, 6% of repeat tests shows
diabetes but 16% show normal glucose
tolerance (NGT), with corresponding fre-
quencies of 13 and 38%, respectively, for
IGT.Insulinresistanceisamajordetermi-
nant of type 2 diabetes and is almost al-
wayspresentbothinpeoplewithIFGand
in people with IGT. Given its association
with CVD risk, she suggested that effects
of insulin resistance must be considered
when examining relationships between
pre-diabetesandCVD.Shesuggestedthat
metabolic syndrome be used as a proxy
for insulin resistance and analyzed rela-
tionships between IGT, IFG, and meta-
bolic syndrome with Strong Heart Study
data beginning in 1988, comprising
4,549AmericanIndiansages45–74years
undergoing three examinations measur-
ing risk factors and preclinical disease
during a 20-year follow-up.
At baseline, 816 had NGT, 1,243 IFG
(using ADA criteria), 619 IGT, 1,420 pre-
diabetes, and 2,222 diabetes—almost
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IFG, IGT, and pre-diabetes led to a three-
fold increase in diabetes risk in the pop-
ulation,leadingHowardtoconcludethat,
in this population, the GTT offered rela-
tively little additional information to that
available from fasting glucose. Triglycer-
ide levels were 105 in NGT, 140 in pre-
diabetic, and 180 in diabetic men, with a
similar stepwise increase in women. In-
termediate glycemia was associated with
an intermediate decrease in HDL, and
there was lower LDL with diabetes and
intermediate lowering with pre-diabetes,
although Howard pointed out that LDL is
altered in composition in states of dysme-
tabolism, becoming more atherogenic.
Macroalbuminuria was somewhat in-
creased with pre-diabetes, the prevalence
of carotid plaque was increased in diabe-
tes but not in pre-diabetes, and echocar-
diographic left ventricular hypertrophy
showed an intermediate elevation with
pre-diabetes. The 7- and 15-year coro-
nary artery disease and stroke risks were,
however, only increased among individ-
uals who had diabetes. Metabolic syn-
drome was present in 10.6 and 21% of
menandwomen,respectively,withNGT,
in57and69%,respectively,ofthosewith
pre-diabetes, and in 69 and 86%, respec-
tively, of those with diabetes. Metabolic
syndrome was also associated with
greater age, BMI, and cigarette use, all of
which increase the likelihood of adverse
outcome. There was a 25% 6-year inci-
dence of diabetes among those with met-
abolic syndrome, compared with a 13%
incidence for those without. Metabolic
syndrome doubled the risk of left ventric-
ular hypertrophy, and there was in-
creasedriskofCVDeventswithmetabolic
syndrome among both diabetic and non-
diabetic individuals.
Certainly,oneneedstoconsiderCVD
risk factor modiﬁcation in diabetic pa-
tients, considering the great deal of data
showing beneﬁts of LDL cholesterol and
blood pressure reduction, and there
should similarly be beneﬁt among pre-
diabetic individuals in preventing diabe-
tes and in treating risk factors. An
important question is whether, with a
moreaccuratemeasureofriskofdiabetes,
those who subsequently develop diabetes
would show increased CVD risk before
diabetesdevelopment,ashasbeenshown
in analysis of the Nurses’ Health Study
(18). Corollary questions include 1)
whether it would be better to (pharmaco-
logically) treat blood glucose elevations
before development of diabetes or to wait
fordiabetestodevelopbeforeinitiationof
pharmacologic diabetes treatment and 2)
what should be the CVD risk factor goals
for pre-diabetic individuals. The clinical
outcome data required to answer these
questions are not available, although sur-
rogate outcomes may give relevant infor-
mation. Recognizing that the very high
diabetes risk of Native Americans may
lead to speciﬁc characteristics of those
populations differing from those of other
groups at lower risk, Howard suggested
that a distinguishing feature may simply
be that this group “got fatter earlier...
[and that] some of the other populations
aren’t as far along this continuum.” Phar-
macologic glucose-lowering interven-
tions might be appropriate for pre-
diabetic individuals with both IFG and
IGT or for those with particularly high-
risk ethnicity, those with IFG plus meta-
bolic syndrome, or, along the lines
described by Stern, those satisfying a risk
score based on multiple markers.
Silva Arslanian (Pittsburgh, PA) dis-
cussed glucose intolerance in youth. In
the National Health and Nutrition Exam-
ination Survey (NHANES) in 1999–
2000, 7% of non-Hispanic white
adolescents in the U.S. between ages 12
and 19 years had IFG (19). She showed a
study of overweight adolescents in which
the correlation of two fasting blood glu-
cose levels was 0.72 while that of two 2-h
postload glucose levels was 0.34, with
meanabsolutedifferencesof4and17mg/
dl, respectively. Fasting glucose, how-
ever, missed 70–90% of youth with
abnormal 2-h glucose, suggesting that in
this population the GTT would be useful
and, perhaps, that it might be reasonable
tofollowthisseriallyforadequatediagno-
sis of pre-diabetes.
In studies of the role of abdominal
obesity in children, both abdominal mag-
netic resonance imaging (20) and waist
circumference (21) predict insulin resis-
tance and increased triglycerides, and
waist circumference at age 13 years pre-
dicts metabolic syndrome in adulthood
NEWS FROM THE FOOD AND DRUG ADMINISTRATION
From time to time, new announcements by the FDA pertaining to aspects of diabetes
treatment will be highlighted in this section.
The FDA has indicated ongoing concern about the use of ezetimibe, announcing
that it intended to investigate the report from the Simvastatin and Ezetimibe in
Aortic Stenosis (SEAS) trial of a possible association between the use of Vytorin
and increased incidence of cancer. Cardiovascular risk was not reduced with the
agent in the study of individuals with aortic stenosis.
Expanding on its October 2007 report of 30 individuals receiving Byetta and
developing pancreatitis, the FDA announced that it had learned of six cases of
hemmorrhagicornecrotizingpancreatitisinpatientsreceivingthisagent,withall
requiringhospitalizationandtwodying.Therearewell-documentedassociations
of pacreatitis with obesity, with dyslipidemia, and with diabetes itself, and pan-
creatitismaybeassociatedwithuseofmanymedicinesgiventodiabeticpatients,
including sulfonylureas, ACE inhibitors/angiotensin receptor blockers, and di-
uretics, such that the expected incidence among the more than 700,000 patients
treated with Byetta might be double or more the expected pancreatitis rate of
somewhere0.01%inthegeneralpopulation—perhaps150cases.Thereported
36 cases, then, represents an unknown fraction of those expected. One might,
then,questiontheFDA’simplicationthatByettaincreasestheriskofpancreatitis,
recognizing that while underreporting of adverse events to the agency might
make any apparent grouping of events potentially serious, there may now be an
opposite effect of the earlier announcement increasing such reporting.
Finally, the FDA announced that it has approved six manufacturers’ inﬂuenza
vaccinesforthe2008-2009season.Everyyear,5-20%oftheU.S.populationgets
inﬂuenza,morethan200,000peoplearehospitalizedfromitscomplications,and
thereare36,000ﬂu-relateddeaths;vaccinationofpeoplewithchronicmedical
conditions such as diabetes and of health care personnel is thus critical. The FDA
newsletter pointed out that just 40% of health care workers in the United States
receive an inﬂuenza vaccination (http://www.fda.gov/bbs/topics/NEWS/2008/
NEW01872.html).
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abolic ﬁtness,” with a subset of over-
weight youth having greater maximal
oxygen consumption with lower visceral
fat than BMI- and percent body fat–
matched control subjects (23). Arslanian
reviewed evidence that the metabolic de-
fect in pre-diabetes in youth involved re-
ducedinsulinsecretion(24,25),withIGT
to a greater extent than IFG associated
with insulin resistance. Both factors are
represented in the disposition index,
which is particularly decreased in youth
with both IFG and IGT (26). This be-
comes even more apparent in type 2 dia-
betes in youth, involving both insulin
resistance and loss of the ﬁrst and second
phases of insulin secretion, leading to a
90% reduction in the glucose disposition
index (27). She described a recent study
from her group showing that a subset of
clinically diagnosed type 2 diabetic chil-
dren have positive GAD, islet-associated,
or islet cell antibodies and tend to have
greater loss of insulin secretion and lesser
insulin resistance, leading to the same re-
duction in disposition index as in those
who have negative antibody levels, with
greater insulin resistance and lesser insu-
lin secretory deﬁciency. Data on compli-
cations are, she noted, somewhat scanty,
but there is evidence that atherosclerotic
complications begin in childhood (28).
Arslanian showed evidence of increased
pulse wave velocity (a measure of arterial
stiffness) in type 2 diabetic children, with
lesserbutstillsigniﬁcantincreaseinobese
nondiabeticchildren(29),indicatingpre-
mature aging of the cardiovascular sys-
tem. Both black and white children with
insulin resistance have increased systolic
blood pressure and triglyceride and de-
creased HDL cholesterol and adiponectin
levels, with evidence of endothelial dys-
function in whites (30) and with IFG as-
sociated with increased blood pressure
and triglyceride levels among adolescents
in NHANES (19). “The big question,” Ar-
slanian concluded, “is what is the tempo
ofprogression....Inpediatricsitisgoing
to be highly difﬁcult to answer this ques-
tion.” To stop the progression to diabetes
in youth, we need to learn how to inter-
vene, what the timeline of obesity-related
diabetes development will be, and what
the magnitude of risk is for a given degree
of obesity.
What is the potential negative effect
of not treating pre-diabetes?
Jaakko Tuomilehto (Helsinki, Finland)
discussed the CVD risk of pre-diabetes
(31). Diabetes and CAD occur together
morecommonlythanusuallyrecognized,
with the negative impact of dysglycemia
apparent before diabetes. In the Diabetes
Epidemiology: Collaborative Analysis of
DiagnosticCriteriainEurope(DECODE),
agroupofstudiesof25,000individuals
were analyzed together, showing that 2-h
glucose levels increased with age, with
less evidence for such an increase in fast-
ing glucose and with 2-h glucose rather
than fasting glucose predicting all-cause
mortality and CVD risk (32). There was a
continuous increase in CVD risk with in-
creasing 2-h glucose, a phenomenon not
clearly found for fasting glucose. Adjust-
ing for fasting glucose, 2-h glucose con-
tinued to signiﬁcantly predict increased
CVD, coronary heart disease (CHD), and
total mortality. Furthermore, although
the absolute risk was greater for diabetic
individuals, in DECODE there were more
excess deaths related to hyperglycemia
among men with IGT than among those
with diabetes because of the greater prev-
alence of the former group, implying that
this group could beneﬁt from treatment.
All-cause mortality was increased to a
greater extent than CVD among individ-
uals with IGT, presumably because of the
increase in cancer mortality, a less well-
recognized adverse association. Diabetes
Epidemiology: Collaborative analysis Of
Diagnostic criteria in Asia (DECODA), a
similar study, showed similar data, with
the effect of fasting glucose on risk elimi-
nated by adjusting for 2-h glucose,
whereas adjustment for fasting glucose
failed to eliminate the association of 2-h
glucosewithCVD,CHD,stroke,andtotal
mortality (33).
Tuomilehto showed data from an un-
published ADA work group on outcomes
of hyperglycemia similarly suggesting
that high 2-h glucose levels carry greater
risk than high fasting glucose, leading
him to suggest that the current recom-
mendation that GTT be performed with
abnormal fasting glucose “doesn’t make
any sense,” as those with normal fasting
glucose may particularly beneﬁt from
identiﬁcation of IGT. Furthermore, he
showed a 10-year follow-up of Finns in
which CVD was similarly increased
among individuals with elevated 2-h glu-
cose who did and who did not subse-
quently develop diabetes, even after
correction for obesity, blood pressure,
lipids, and cigarette use. The increase in
CVD and total mortality associated with
newly diagnosed diabetes is not as well
seen at 0–5 years as at 5–10 and 10–15
years (34), suggesting that diabetes may
differfromotherriskfactorsinrequiringa
very long follow-up for demonstration of
adverse effect. Studies in Europe (35) and
Asia (36) show that the minority of indi-
vidualswithheartdiseasehaveNGT,with
measurement of fasting glucose alone in-
sufﬁcienttoascertainglycemicabnormal-
ity in this group (37), and that there is
reducedsurvivalinindividualswithheart
disease found to have diabetes (38), fur-
ther suggesting the importance of assess-
ing glucose tolerance. In this study, the
minority of newly identiﬁed diabetic pa-
tients received glucose-lowering drugs,
but those so treated showed a signiﬁcant
threefold reduction in cardiovascular
events (39). Interestingly, a study of indi-
viduals with myocardial infarction
showed that among those having diabe-
tes, the use of -blockade, renin-
angiotensin inhibition, antiplatelet
treatment, and statins reduced mortality,
whereas this was not demonstrated for
those without diabetes. Similarly, in this
study, revascularization was highly bene-
ﬁcial for the diabetic but not for the non-
diabetic subgroup (40). Although these
studies cannot distinguish beneﬁts of
treatment from underlying differences
in characteristics of patients and/or
providers, there is a body of evidence
favoring diabetes identiﬁcation and
treatment for individuals with heart
disease.
Similar studies suggest association of
glycemia with cerebrovascular disease.
Carotid intima-media thickness (IMT) is
increased in people with diabetes and, to
a lesser extent, in those with pre-diabetes
(41). The majority of people with stroke
have evidence of glycemic abnormality
when glucose tolerance testing is per-
formed (42). Finally, the risk of recurrent
stroke is increased with glycemic abnor-
mality (43).
TuomilehtoreviewedtheFINnishDi-
abetes RIsk Score (FINDRISC) for pre-
dicting 10-year risk of type 2 diabetes in
adults (available at www.diabetes.ﬁ/
english), with age, BMI, waist circumfer-
ence, daily physical activity, dietary
vegetables and fruits, diagnosis of hyper-
tension and abnormal glucose levels, and
family history of diabetes used to calcu-
late a score that he showed to strongly
correlate with 10-year diabetes risk (44),
with each 1-point increase in the score
associated with a 16–23% increase in
likelihood of CVD and mortality (45).
Diabetes prevention with lifestyle in-
tervention has been shown in the U.S. Di-
Bloomgarden
DIABETES CARE, VOLUME 31, NUMBER 10, OCTOBER 2008 2065abetes Prevention Program (DPP) (46);
the Finnish Diabetes Prevention Study
(47), in which the intervention was most
effective in the highest-risk group, with
ongoing beneﬁt for 4 years after the con-
clusionoftheformallifestyleintervention
(48);andintheChineseDaQingDiabetes
Prevention Study, with separation be-
tween the control and intervention
groups maintained for a 20-year period
(49). Based on the differences reported in
the DECODE analysis, Tuomilehto sug-
gested that treatment to reduce 2-h glu-
cose by 2 mmol/l/l would reduce adverse
outcomes by 20%. These interventions
could then be of great beneﬁt, although it
will be important that adequately pow-
ered studies with sufﬁciently long fol-
low-up are carried out.
Robert Ratner (Washington, DC) dis-
cussed the potential impact of diabetes
prevention on micro- and macrovascular
disease based on data from the DPP. Does
diabetesprevention,heasked,reducemi-
crovascular disease, decrease CVD risk
factors, reduce intermediate end points,
or decrease events?
Diabetes prevention might reduce
microvascular disease, although this is
based on limited data. In the DPP, dia-
betic retinopathy occurred in 7.9% of
those not developing diabetes but in
12.6%ofthosewhodiddevelopdiabetes,
with mild-to-moderate nonproliferative
diabetic retinopathy developing in 1.0 vs.
1.8% and microaneurisms in only 6.9 vs.
10.8% of subjects, respectively (50).
Similarly, regardless of treatment with
placebo, metformin, or lifestyle modiﬁca-
tion, those who progressed to diabetes
had greater likelihood of worsening mi-
croalbuminuria,withanet1%increasein
prevalence of microalbuminuria in the
placebo group, no change among those
assigned to metformin, and a 1.3% de-
crease with the lifestyle intervention. In
the Diabetes REduction Assessment with
ramipril and rosiglitazone Medication
(DREAM) trial, 9.2% of those receiving
rosiglitazone, but 10.8% of the placebo
group, progressed from normo- to mi-
croalbuminuria,similarlysuggestingben-
eﬁt of treatment (51).
ParticipantsintheDPPhaddecreased
blood pressure, in association to a lesser
extent with metformin than with lifestyle
modiﬁcation, with lifestyle modiﬁcation
patients having a reduction in need for
antihypertensive treatment (52). In the
STOPtype2diabetesstudywithacarbose
(53) and in the DREAM study with ros-
iglitazone, blood pressure similarly bene-
ﬁted.IntheDPP,LDLdecreasedsimilarly
withmetforminandlifestyle,andforHDL
cholesterol and triglyceride levels the life-
style group showed greater beneﬁt.
Among the 1,079 DPP participants in the
placebo group, blood pressure, triglycer-
ide, HDL cholesterol, and LDL size im-
proved in the 154 subjects developing
NGT while worsening in the 191 pro-
gressing to type 2 diabetes. Of those not
havingmetabolicsyndromeatentry,two-
thirdsoftheplacebogroupdevelopedthe
syndromeduringthestudyperiod;devel-
opment of metabolic syndrome was re-
duced 17% with metformin and 41%
with the lifestyle intervention (54). Levels
of tissue plasminogen activator, plasmin-
ogen activator inhibitor-1, and C-reactive
protein similarly showed greatest improve-
ment with lifestyle intervention, intermedi-
ateimprovementwithmetformin,andlittle
change or worsening in the placebo group
(55). Diabetes prevention does, then, ap-
pear to reduce CVD risk.
There are limited data on surrogate
end points, with evidence of beneﬁt in
carotid intima-media thickness in the
Troglitazone in Prevention of Diabetes
(TRIPOD) study with troglitazone (56)
and in the STOP-type 2 diabetes study
with acarbose (57). Ratner reviewed a
model based on data from the DPP sug-
gesting that, with metformin and lifestyle
treatmentdelayingmeantimetodevelop-
ment of diabetes by 3.4 and 11.1 years,
respectively, the development of blind-
ness and renal failure would be reduced
20 and 40% and there would be 25 and
45% reductions in amputation, respec-
tively, with lesser relative but greater ab-
solute decreases in stroke and CHD (58).
Lifetime costs of the interventions are
minimal or even cost-saving, he pointed
out, and “in essence the costs of pre-
diabetes will be paid later if we don’t do
anything today.” Is it possible to carry out
a trial demonstrating such beneﬁt? To
prove, say, that diabetes prevention re-
duces CVD events—with an annual CVD
event rate of 1.5 and a 25% risk reduc-
tion—for the statistical certainty to be
0.05andthetrialpowertobe90%,3-,5-,
and 10-year studies would require
28,000,14,700,and6,800people.Actual
annual CVD rates might be 0.5–1%, and
the degree of reduction might only be
5–15%, further increasing the number of
participantsrequiredtosuccessfullycarry
out such a study. Also, there may well be
a lag period, as suggested by Tuomilehto,
of over 5 years, beginning at the time of
development of diabetes, such that the
trial would require at least a decade.
Would it, however, be ethical to have a
placebo control group if we know that a
safe intervention such as lifestyle reduces
diabetes development by more than half?
Ratner concluded that although diabetes
prevention may well reduce CVD events,
“it is going to be very difﬁcult to prove.”
George Bakris (Chicago, IL) discussed
issues of the impact of pre-diabetes on ne-
phropathy and hypertension. He pointed
out that microalbuminuria is a marker,
not a risk factor, as it has not fully been
showntoaffectthecourseofrenaldisease
or CVD when taking all other factors into
account.Furthermore,inadditiontohav-
ing 20–25% biologic variability, the as-
says themselves have 5–10% variability,
such that a 30% change is required for
meaningful beneﬁt. Bakris pointed out
that many inﬂammatory conditions are
associated with microalbuminuria, with
albuminuria improving when they re-
solve. The Diabetes Control and Compli-
cations Trial appears to be the only study
showing a relationship between glycemia
and albuminuria, although a number of
preclinical studies support this effect.
Bakris noted that the usual upper limit of
normal for urine microalbumin, 30 mg/g
creatinine, is unlikely to be correct, sug-
gesting that 20 or even 15 may be the
better cutoff. Albuminuria is strongly as-
sociated with CVD, in a fashion additive
to the association with blood pressure
(59). Bakris pointed out that the relation-
shipbetweenmicroalbuminuriaandCVD
is considerably stronger than that of CRP
with CVD, such that he did feel this to be
a useful measure (60). Macroalbuminuria
is an even stronger CVD risk factor (61).
Bakris considered glomerular ﬁltra-
tionrate(GFR)asturdiermeasureofrenal
disease than urinary albumin. Based on
creatinine clearance, 15.5% of the adult
U.S. population has stage 3 chronic kid-
ney disease (CKD) with GFR 30–59 ml/
min,whereasonly1%ofthepopulation
has GFR 30 ml/min (62). More than re-
nal failure, the great risk of CKD is its
associated increase in CVD, with a Medi-
care database showing that CKD and
diabetes are additive in causing cerebro-
vascular disease, coronary artery disease,
congestive heart failure, and amputation
or peripheral arterial insufﬁciency.
The greatest challenge in preventing
progressionofCKDanditscomplications
is the treatment of hypertension. Most
groups suggest goal blood pressure levels
130/80 mmHg, recommending renin-
angiotensin system (RAS)-based treat-
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commented that reduction of blood pres-
sure should be the overriding consider-
ation, with multiple drugs usually
required (63). Taken together, Bakris
stated, it appears that with systolic blood
pressure 135 mmHg, the rate of fall in
GFR stabilizes at 2m l  min
1   year
1.
There appears to have been modest im-
provement in blood pressure awareness,
treatment,andcontrolfrom1999to2004
(63a).High-riskpopulations,particularly
black and Hispanic, have the poorest
bloodpressurecontrol(64).Dietarysaltis
important for limiting the beneﬁt of RAS-
based treatments. Sodium intake 4
g/daymaydecreasetheantiproteinuricef-
fectofRASblockadebyhalf(65),andthis
is only partially restored with thiazide di-
uretics (66). The DASH study showed
that changes in albuminuria with lifestyle
modiﬁcation focused on sodium intake
leads to reduction in albuminuria (67).
Bakris described a study comparing
losartan plus hydrochlorothiazide with
trandolapril plus verapamil in 240 indi-
viduals with IGT, showing the former to
be associated with a 20–25 mg/dl in-
crease in 2-h postload glucose and eleva-
tions in insulin levels and with a 9 vs. 2%
likelihood of diabetes development, re-
spectively(68).Asimilarstudyofbenaza-
pril-treated patients is in progress
comparing the addition of hydrochlo-
rothiazide vs. amlodipine (69) and ad-
dressing the question of whether the
thiazide diuretic hydrochlorothiazide,
even in doses not exceeding 25 mg, has
adverse effects on glycemia.
Aaron Vinik (Norfolk, VA) discussed
neurovascular dysfunction in pre-
diabetes, reporting his ﬁndings that 11
and 13% of individuals with IFG and IGT
had polyneuropathy, with 4 and 9% hav-
ing neuropathic pain, respectively. This
phenomenonofIGTneuropathyhasbeen
reported by a number of groups (70,71),
with one-third to one-half of individuals
with idiopathic sensory neuropathy hav-
ing IGT (72) and IGT occurring in two-
thirds of individuals with idiopathic
painful neuropathy (73). Abnormal auto-
nomic function is also associated with
pre-diabetes—as demonstrated by spec-
tral analysis of heart rate variability,
which is a measure of sympathetic and
parasympathetic function useful in dem-
onstrating this association—and is per-
haps associated with IGT but not IFG
(74).Lifestyleinterventionwasassociated
with a 25% reduction in development of
autonomic neuropathy in the DPP (75).
Autonomicneuropathyalsomayhavepe-
ripheraleffectscausingabnormalityofva-
somotion and thermoregulation with
edema(76)inassociationwithabnormal-
ity of small C-ﬁber nerves (77). The con-
sequent impairment in gravitational
blood ﬂow correlates with systolic blood
pressure, C-peptide, LDL cholesterol,
triglycerides, and low HDL cholesterol
(78). Vinik presented a study with pho-
tomicrographs of skin biopsy specimens
showing reduction in intraepidermal
nerve ﬁbers in the proximal leg in associ-
ation with metabolic syndrome as well as
diabetes, with evidence that such abnor-
malities improve with lifestyle interven-
tion (79). Cardiac autonomic neuropathy
may also be associated with silent myo-
cardial infarction (76), perhaps explain-
ing the association of sudden death with
pre-diabetes (80).
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